Compare BioNTech SE - ADR (BNTX) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNTech SE - ADR vs Global X NASDAQ 100 Covered Call ETF — how do they compare? BioNTech SE - ADR trades at $89.89 (market cap $22.86B), while Global X NASDAQ 100 Covered Call ETF trades at $18.46. The key difference: Global X NASDAQ 100 Covered Call ETF is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals.
| BNTX | QYLD | |
|---|---|---|
Market Cap | $22.86B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $119.34 | $18.52 |
52-Week Low | $83.89 | $16.46 |
Enterprise Value | $6.53B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BioNTech (BNTX) trades at $90.07, down 1.55% today, amid a bearish technical signal and declining revenue trends. The company reported a net loss of $1.14 billion in 2025, with profitability metrics negative, though it maintains a strong cash position of $16.78 billion. Recent news highlights restructuring efforts, including site closures and a $1 billion share buyback, as it pivots focus to oncology pipeline development following reduced COVID-19 vaccine demand.
The outlook remains challenging with persistent losses and competitive pressures, but analyst consensus is bullish with a $129.67 price target. Key risks include execution of the oncology strategy and revenue volatility. The stock's current valuation reflects uncertainty, offering potential upside if pipeline milestones are met, but investors face significant operational and market headwinds.
QYLD trades at $18.15, down 1.68% on the day, with technical indicators showing a neutral overall signal. The ETF's covered call strategy generates high monthly distributions but has historically lagged the Nasdaq-100's total return, with recent news highlighting NAV erosion despite consistent dividend payouts. Moving averages suggest a bullish trend while oscillators remain neutral, with all key support and resistance levels clustered around $18.
The outlook remains cautious as QYLD's high yield comes at the cost of capital appreciation potential. While attractive for income-focused investors, the strategy underperforms in strong bull markets. Key risks include capped upside and competitive pressure from lower-fee alternatives like GPIQ, requiring investors to prioritize income generation over growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
